Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
ATG-031 for Cancer
Recruiting1 awardPhase 1
New Haven, Connecticut
"This trial, also known as PERFORM, is studying ATG-031 in patients with advanced solid tumors or B-NHL. It includes two phases - Dose Escalation and Dose Expansion
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service